Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Mariusz S. Wiglusz"'
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 16 (2023)
Externí odkaz:
https://doaj.org/article/d4d6b7c867564fce830efbfbcd5fcfa1
Publikováno v:
Brain Sciences, Vol 13, Iss 9, p 1262 (2023)
Major depressive disorder and bipolar disorder are the leading causes of global disability. Approximately 50% of patients fail to attain remission, prompting a pronounced focus on the significance of dietary patterns and specific nutrients within the
Externí odkaz:
https://doaj.org/article/135bf614e8ec4fc0969f96ae50ad0e50
Autor:
Maria Gałuszko-Węgielnik, Zuzanna Chmielewska, Katarzyna Jakuszkowiak-Wojten, Mariusz S. Wiglusz, Wiesław J. Cubała
Publikováno v:
Brain Sciences, Vol 13, Iss 1, p 142 (2023)
Psychotic treatment-resistant depression is a complex and challenging manifestation of mood disorders in the clinical setting. Psychotic depression is a subtype of major depressive disorder characterized by mood-consistent hallucinations and/or delus
Externí odkaz:
https://doaj.org/article/9f0ec9c919924e548d84d752b06dd7fd
Autor:
Alina Wilkowska, Łukasz Szałach, Jakub Słupski, Aleksandra Wielewicka, Małgorzata Czarnota, Maria Gałuszko-Węgielnik, Mariusz S. Wiglusz, Wiesław J. Cubała
Publikováno v:
Frontiers in Psychiatry, Vol 11 (2020)
There is a growing evidence for the rapid and robust antidepressive effect of ketamine in unipolar and bipolar treatment resistant depression although evidence for the risk of affective switch is still limited. This case presents bipolar I disorder p
Externí odkaz:
https://doaj.org/article/0d127b897ff242659210835e29baa1cf
Publikováno v:
Cells, Vol 11, Iss 4, p 645 (2022)
Background and Objectives: Ketamine is a rapid-acting antidepressant with proven efficacy as an add-on agent in unipolar and bipolar treatment-resistant depression. Although many studies have been published, there is still not enough data on the effe
Externí odkaz:
https://doaj.org/article/5415e3a0760b4b1db1d93736b30fe830
Publikováno v:
Frontiers in Psychiatry, Vol 10 (2019)
Bipolar disorder is associated with a high risk of suicide attempts and suicide deaths. The suicide mortality of people with bipolar disorder is approximately 25 times higher than the general population. No approved pharmacological strategies for sui
Externí odkaz:
https://doaj.org/article/e597b4f3280c48b885b93cf0c39efc91
Publikováno v:
Neurologia i Neurochirurgia Polska. 55:351-356
Introduction. Epilepsy is one of the world’s most prevalent noncommunicable diseases and tends to have a chronic course, often with comorbid psychiatric disorders, of which depressive disorders (DDs) and anxiety disorders (ADs) are the most common.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a390ef718bf898bd0081132c9e54427b
https://doi.org/10.5603/pjnns.a2021.0047
https://doi.org/10.5603/pjnns.a2021.0047
Autor:
Michał Pastuszak, Mariusz S Wiglusz
Publikováno v:
Journal of Psychopharmacology. :026988112311696
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2427bbba12ee49522ef5eea0ce5139a
https://doi.org/10.1177/02698811231169647
https://doi.org/10.1177/02698811231169647
Autor:
Michał Pastuszak, Mariusz S. Wiglusz
Publikováno v:
British Journal of Clinical Pharmacology. 89:1908-1908
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d478edfb926105cb46b056a54542cdba
https://doi.org/10.1111/bcp.15723
https://doi.org/10.1111/bcp.15723
Autor:
Alina Wilkowska, Adam Włodarczyk, Wiesław Jerzy Cubała, Mariusz S. Wiglusz, Maria Gałuszko-Węgielnik
Publikováno v:
Frontiers in Psychiatry
Frontiers in Psychiatry, Vol 12 (2021)
Frontiers in Psychiatry, Vol 12 (2021)
Anhedonia constitutes one of the main symptoms of depressive episode. It correlates with suicidality and significantly effects the quality of patient's lives. Available treatments are not sufficient against this group of symptoms. Ketamine is a novel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c791912e41e80c463eb1b828c6b5287f
http://europepmc.org/articles/PMC8558390
http://europepmc.org/articles/PMC8558390